Perkins Capital Management Inc. decreased its position in ImmunoGen, Inc. (NASDAQ:IMGN – Free Report) by 29.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 12,100 shares of the biotechnology company’s stock after selling 5,100 shares during the period. Perkins Capital Management Inc.’s holdings in ImmunoGen were […]